CURR HEMATOL MALIG R 润色咨询

Current Hematologic Malignancy Reports

出版年份:暂无数据 年文章数:465 投稿命中率: 开通期刊会员,数据随心看

出版周期:Quarterly 自引率:8.0% 审稿周期: 开通期刊会员,数据随心看

前往期刊查询

投稿信息

投稿信息
审稿费用
暂无数据
版面费用
暂无数据
中国人发表比例
2019年中国人文章占该期刊总数量暂无数据 (2018年为暂无数据)
自引率
8.0 %
年文章数
465
期刊官网
点击查看 (点击次数:2483)
点击查看 (点击次数:983次)
作者需知
点击查看 (点击次数:193次)
偏重的研究方向
暂无数据
期刊简介
稿件收录要求
Current Hematologic Malignancy Reports provides in-depth review articles contributed by international experts on the most significant developments in the field. By presenting clear, insightful, balanced reviews that emphasize recently published papers of major importance, the journal elucidates current and emerging approaches to the diagnosis, treatment, management, and prevention of conditions associated with hematologic malignancy.

This journal intends to provide clear, insightful, balanced contributions by international experts that review the most important, recently published clinical findings related to the diagnosis, treatment, management, and prevention of hematologic malignancy. 

We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas, such as leukemia, lymphoma, myeloma, and T-cell and other lymphoproliferative malignancies. Section Editors, in turn, select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An international Editorial Board reviews the annual table of contents, suggests articles of special interest to their country/region, and ensures that topics are current and include emerging research. Commentaries from well-known figures in the field are also provided.